MedTrace Logo

Clinical Trials

NCT05199285 | TERMINATED | PHASE2
15 participants

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2023-01-19
Completion:
2026-02-01
Conditions
  • BCLC Stage B Hepatocellular Carcinoma
  • BCLC Stage C Hepatocellular Carcinoma
  • Locally Advanced Hepatocellular Carcinoma
  • Metastatic Hepatocellular Carcinoma
  • Stage III Hepatocellular Carcinoma AJCC v8
  • Stage IIIA Hepatocellular Carcinoma AJCC v8
  • Stage IIIB Hepatocellular Carcinoma AJCC v8
  • Stage IV Hepatocellular Carcinoma AJCC v8
  • Stage IVA Hepatocellular Carcinoma AJCC v8
  • Stage IVB Hepatocellular Carcinoma AJCC v8
  • Unresectable Hepatocellular Carcinoma
Interventions
  • BIOLOGICAL
No Results Yet
NCT05168163 | RECRUITING | PHASE2
122 participants

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2022-05-27
Completion:
2026-06-30
Conditions
  • Locally Advanced Hepatocellular Carcinoma
  • Metastatic Hepatocellular Carcinoma
  • Stage III Hepatocellular Carcinoma AJCC v8
  • Stage IIIA Hepatocellular Carcinoma AJCC v8
  • Stage IIIB Hepatocellular Carcinoma AJCC v8
  • Stage IV Hepatocellular Carcinoma AJCC v8
  • Stage IVA Hepatocellular Carcinoma AJCC v8
  • Stage IVB Hepatocellular Carcinoma AJCC v8
  • Unresectable Hepatocellular Carcinoma
Interventions
  • BIOLOGICAL
  • DRUG
No Results Yet
NCT05111574 | ACTIVE_NOT_RECRUITING | PHASE2
101 participants

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2022-08-11
Completion:
2027-07-15
Conditions
  • Anal Melanoma
  • Bladder Melanoma
  • Cervical Melanoma
  • Esophageal Melanoma
  • Gallbladder Melanoma
  • Head and Neck Mucosal Melanoma
  • Mucosal Melanoma
  • Nasopharyngeal Mucosal Melanoma
  • Oral Cavity Mucosal Melanoma
  • Penile Mucosal Melanoma
  • Rectal Melanoma
  • Recurrent Mucosal Melanoma
  • Sinonasal Mucosal Melanoma
  • Urethral Melanoma
  • Urinary System Mucosal Melanoma
  • Vaginal Melanoma
  • Vulvar Melanoma
Interventions
  • PROCEDURE
  • BIOLOGICAL
  • DRUG
No Results Yet
NCT05080166 | COMPLETED | NA
74 participants

UPLYFT For Lymphoma Survivors

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2022-02-08
Completion:
2026-07-17
Conditions
  • Lymphoma
  • Survivorship
Interventions
  • OTHER
  • BEHAVIORAL
No Results Yet
NCT04969926 | RECRUITING
3000 participants

Natural History Study of Parathyroid Disorders

Study Type:
OBSERVATIONAL
Last Updated:
2026-08-04
Start Date:
2021-11-30
Completion:
2031-01-22
Conditions
  • Parathyroid Cancer
  • Primary Hyperparathyroidism
  • Pseudohypoparathyroidism
  • Inheritable Bone Diseases
  • Multiple Endocrine Neoplasia, Type 1
No Results Yet
NCT04949100 | ACTIVE_NOT_RECRUITING | NA
50 participants

Microcurrent for Fibromyalgia

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-10-25
Completion:
2026-12-31
Conditions
  • Fibromyalgia
Interventions
  • DEVICE
No Results Yet
NCT04943861 | RECRUITING | NA
200 participants

Human Immunodeficiency Virus (HIV) Food Insecurities

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2023-12-01
Completion:
2027-02-28
Conditions
  • Food Insecurities
  • Cardiometabolic Comorbidities
  • HIV
  • PreDiabetes
  • Type 2 Diabetes Mellitus (T2DM)
Interventions
  • BEHAVIORAL
  • OTHER
No Results Yet
NCT04847063 | RECRUITING | PHASE1
60 participants

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-10-19
Completion:
2033-12-30
Conditions
  • Peritoneal Mesothelioma
  • Peritoneal Carcinomatosis
  • Ovarian Cancer
  • Gastrointestinal Cancer
  • Appendiceal Cancer
  • Atypical Mesothelial Proliferation
  • Colorectal Cancer
Interventions
  • DRUG
  • PROCEDURE
No Results Yet
NCT04739800 | ACTIVE_NOT_RECRUITING | PHASE2
120 participants

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-06-10
Completion:
2023-01-26
Conditions
  • Fallopian Tube Mucinous Adenocarcinoma
  • Ovarian Seromucinous Carcinoma
  • Platinum-Refractory Fallopian Tube Carcinoma
  • Platinum-Refractory Ovarian Carcinoma
  • Platinum-Refractory Primary Peritoneal Carcinoma
  • Recurrent Fallopian Tube Clear Cell Adenocarcinoma
  • Recurrent Fallopian Tube Endometrioid Adenocarcinoma
  • Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
  • Recurrent Fallopian Tube Mucinous Adenocarcinoma
  • Recurrent Fallopian Tube Transitional Cell Carcinoma
  • Recurrent Fallopian Tube Undifferentiated Carcinoma
  • Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma
  • Recurrent Ovarian Clear Cell Adenocarcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma
  • Recurrent Ovarian High Grade Serous Adenocarcinoma
  • Recurrent Ovarian Low Grade Serous Adenocarcinoma
  • Recurrent Ovarian Mucinous Adenocarcinoma
  • Recurrent Ovarian Seromucinous Carcinoma
  • Recurrent Ovarian Transitional Cell Carcinoma
  • Recurrent Ovarian Undifferentiated Carcinoma
  • Recurrent Platinum-Resistant Fallopian Tube Carcinoma
  • Recurrent Platinum-Resistant Ovarian Carcinoma
  • Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
  • Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
  • Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
  • Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
  • Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
  • Recurrent Primary Peritoneal Transitional Cell Carcinoma
  • Recurrent Primary Peritoneal Undifferentiated Carcinoma
  • Refractory Fallopian Tube Clear Cell Adenocarcinoma
  • Refractory Fallopian Tube Endometrioid Adenocarcinoma
  • Refractory Fallopian Tube High Grade Serous Adenocarcinoma
  • Refractory Fallopian Tube Mucinous Adenocarcinoma
  • Refractory Fallopian Tube Transitional Cell Carcinoma
  • Refractory Fallopian Tube Undifferentiated Carcinoma
  • Refractory Low Grade Fallopian Tube Serous Adenocarcinoma
  • Refractory Ovarian Clear Cell Adenocarcinoma
  • Refractory Ovarian Endometrioid Adenocarcinoma
  • Refractory Ovarian High Grade Serous Adenocarcinoma
  • Refractory Ovarian Low Grade Serous Adenocarcinoma
  • Refractory Ovarian Mucinous Adenocarcinoma
  • Refractory Ovarian Seromucinous Carcinoma
  • Refractory Ovarian Transitional Cell Carcinoma
  • Refractory Ovarian Undifferentiated Carcinoma
  • Refractory Primary Peritoneal Clear Cell Adenocarcinoma
  • Refractory Primary Peritoneal Endometrioid Adenocarcinoma
  • Refractory Primary Peritoneal High Grade Serous Adenocarcinoma
  • Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma
  • Refractory Primary Peritoneal Transitional Cell Carcinoma
  • Refractory Primary Peritoneal Undifferentiated Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
Results Available
NCT04708418 | ACTIVE_NOT_RECRUITING | PHASE2
60 participants

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-10-15
Completion:
2026-12-31
Conditions
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Melanoma of Unknown Primary
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIID Cutaneous Melanoma AJCC v8
  • Recurrent Cutaneous Melanoma
Interventions
  • PROCEDURE
  • BIOLOGICAL
  • DRUG
No Results Yet
NCT04676529 | COMPLETED | PHASE1/PHASE2
43 participants

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-04
Start Date:
2021-02-18
Completion:
2025-07-09
Conditions
  • Myelofibrosis
  • Primary Myelofibrosis (PMF)
  • Post- Essential Thrombocythemia Myelofibrosis
  • Post Polycythemia Vera Myelofibrosis
Interventions
  • DRUG
Results Available
Previous
Sorted by latest updates
Next
Showing 40 trials per page